us and afternoon second everyone conference joining on Thank listening. Thank for you, Bill call. to our XXXX you good quarter
assets near clinical over therapeutics us clinical plan of months. momentum. from key I commercializing than continues see you significant of ultimate we XX will the to Today molecule that our for market lay unique top next term trials small towards goal readouts the five fewer we release no of out data line to progress as Our ahead gain sequence the
forward and data top foremost, Phase First of we of advocate and our announcing ANCA-associated the trial pivotal fourth this vasculitis drug the line look of in to avacopan from III year. candidate quarter
fairly Japan world. the ADVOCATE. you. start only this efficiently patients me cohort Let Notably, enrolled a and for the to Accordingly, Ultimately, down study, than XX addition originally of planned five not late for XXX a the from little break enrollment, enrollment this enrolled later sets. country study global later the within countries. a they data bit to the to the was weeks Japan ADVOCATE despite of Japan we completed very rest decided cohort was include of But
trial features for mid This year, data data release that X. vivo of QX. the in in pharmacological to can are Slide does as the on experiments overall well foundation, ADVOCATE as they models, expect seen have well this Informed be we late solid A controlled and to ADVOCATE continue change of QX our on that noted uncontrolled and built long humans. encouraged a observers clinical is in not results now release, guidance of reminder projecting advocate
in in experiments great vivo demonstrate in specifically the established example, model the well receptor this innovation and in mechanism receptor of pharmacological controlled detail. fact, compliment is There the literature. role and action of that carefully genetic vasculitis, CXa For in the ANCA-associated of in are CXa disease
neutrophils obtaining receptor to the thus ankle a is demonstrate beneficial that and models cause sufficient result. receptor receptor blocking receptor the that disease. Accordingly, show is CXa important only data in targets point CXa shown CXa been not achieves same avacopan is bearing a CXa that that necessary activation therapeutic be of But those stifling CXa specifically stage of as a this receptor activation to and CXa necessary block An pro-inflammatory that Animal to beneficial that and the receptor symptomatology. cause the in stressed CX avacopan have for known It avacopan the receptor. CXLX. the is does second disease
vivo say target CXLX CXa data human in or beneficial successful because rise to the is if many actions reason via two important best will, avacopan, studies, the validated quite have ANCA is shown the And trials. also including from multicenter, specifically and receptor clinical this is randomized, can vasculitis. ligand CXLX. and to not phase CLASSIC CXa you give controlled ANCA we healthy CXa patients. for from endeavored previous always trials important good II placebo and to be effects vasculitis in This trials are to has model pro CLEAR of the clear, These been have the since An enhanced
proteinuria this randomized glomerular controlled of which stabilizing ANCA of noxious of rapidly doses that kidney did function for impaired in need patients kidney Avacopan active treating CLEAR And Always prednisone avacopan avacopan the symptoms levels of all was to that of eventually control in rates. currently and brought while patients the patients. signs terms dysfunction. as under trial a rapidly signs clinical brought study filtration vasculitis such also acute ANCA in disease CLEAR used without to The reducing and methylprednisolone rapidly high ANCA avacopan normal neutrophils demonstrated are symptoms steroids have and daily in and most good control.
of met even added current standard controlled of profile, the top placebo trial on Furthermore, when of trial the regimen. care safety avacopan CLASSIC goal another avacopan with supporting a its randomized
than avacopan XXX each the more are involving sites in with regimen arm. before ADVOCATE double continuing around the control whether so expands It trial patients III global XX protocol, steroids trials. like learned or a Phase dummy do they on Our we truly what randomized double a countries blind in know Phase that is CLEAR patients II not the study XXX ADVOCATE it, is receiving world. in
vasculitis of Importantly to with alleviate patients. may both of as controlled the from we the suffering as of the burden like the ADVOCATE avacopan studies much Based use for of that CLEAR, curb ANCA data patients we of in believe mortality total today, vasculitis the are steroids in well morbidities. chronic terms so aim on responsible ANCA disease
the vasculitis care; fourth Medicines arresting quality aims beyond burden scope As both to if the Activity BVAS, kidney European X, signs improvement marked the you to measure disease. with measured vasculitis; rather rapid diminution know the we Vasculitis patient aim and episode Slide does the damage first, of from the of current therapy not go in broader active truly severe to These the organs, lasting of a but reform life. data and Score or can that see consequences measures a third, and four pronged symptoms, from second, have far limited interested well. and is the FDA the we of in standard Birmingham in Agency solely a end the avacopan; of and significant acute which And total are acute notably the concerning the
for other least trial, months. of period BVAS will the for based experts which to key five, based will into on we controlled The vasculitis the score the alleviating And while So of are will for take steroids BVAS the from weeks, since at as immunosuppressants, a measure also discussions BVAS helped on account six primary four ANCA are being endpoints off total burden assessed as we by secondary disease. look be of measured of to remission in steroids about XX regulators two primary XX this and and endpoints first also endpoints, confident time after zero weeks. shown slide weeks, that a at runs at first in use conventionally randomized
The null disruptive And and as incumbent XX. can instance, the the even only used in such that or can hypothesis to liabilities, BVAS a is when endpoint be primary one case null and such pragmatically new be contemplated the which used. of since ANCA present hypothesis fact, an non-inferiority includes pragmatically in is hypothesis the significant as safety diseases XX therapy to such doses certainly the null weeks have high small, is is is regimen fact, in this statistical of orphan to the that number that N This only patient known trials, appropriate test at is null as in ANCA that and tends therapy unseat in appropriate be NI hypothesis steroids. is pivotal statistical with NI chronic non-inferiority that or ADVOCATE.
Phase ANCA This based FDA been approval pivotal III statistical RAVE of in chronic compared previously rituximab well cyclophosphamide is specifically hypothesis as It approved that in ANCA an high was that be statistical for the on vasculitis, achieving has but that trial. established null the coupled the to an of resulted steroids. to to other test solely to when in doses non-inferiority study always rituximab pivotal only noted in alternative cyclophosphamide, steroids plus of
extensive X of me reached turn known our kidney today. CCXXXX with of lead condition as enrollment milestone LUMINA approved We week. unique chemokine patients dialysis. is X. patient trial Let another inhibitor expensive primary be Slide in final failure, Focal therapeutic to for the is renal on treatment to there the Glomerulosclerosis now expect which patient an treatment administered as agent, next by we our orally or and receptor orphan our Segmental and requiring can randomized CCXXXX FSGS CCRX FSGS second to in illustrated no completing It recently
working CCRX on elevating the to in blood. development develops patients filter team waste and the begin discovery scientific from that Our Proteins has In into glomeruli, of those urine FSGS. role to the leak scar the parts inhibition with of tissue proteinuria. FSGS kidneys the on been
and profile with inhibitor in chronic sometimes demonstrated or nephropathy, proteinuria kidney reduction several an hundred called diabetic our orally selective diabetic good with DN. is in a patients administered durable CCXXXX a in DCKD safety disease, we and CCRX Phase previously rapid II
because, we endpoint. a in fact that the registration the pivoted DCKD indicated FSGS which trials in with from reduction We unlike potentially was primary endpoint, FDA DCKD to DCKD, successfully can allowing In has proteinuria achieved FSGS proteinuria importantly, CCXXXX. be
in Our randomized in of trial is a all of a weeks. protein LUMINA XX the drop FSGS of The controlled patients, high at proteinuria placebo have levels X endpoint primary whom is urine. study
year. the in the to trial, of progress release top the half we coming our Given data line in X first expect LUMINA
study enroll primary to label our X and more proteinuria with single severe condition. open FSGS, continue a arm LUMINA rarer patients we of Meanwhile, nephritic
too that We expect to during report XXXX. trial out
you rights While ANCA States. ChemoCentryx our the been remind granted in to for CCXXXX Pharma has avacopan for I will commercial retains United that both the of FSGS, Vifor and international rights partner all vasculitis
prepare capability actively the to integration. forward our our take are in commercial We as step building we final
glomerulopathy, CX forward readout to of trial threatening. which line another looking life another are diversify kidney our to disease, top rare avacopan be from data We the in can XXXX in treatment
to XX of trial a Our ACCOLADE two CXG index on the seen CXG therapy. in avacopan ACCOLADE the be Slide can randomized of each avacopan be reached the care after has months of in The six strata current of the controlled six of standard the trial primary will trial patients in and change endpoint overall halfway is percentage mark treatments. of comparing histologic X. after months
in us We time filtration we those receiving over allow KOLs and are surrounding encouraging feedback also which measuring noting are that worth during It of to the will reductions changes practice clinical track very changes in our measurements. taking rates. is relate biopsies histological proteinuria from changes and to trial, glomerular
biopsies. CXG current require Other not do trials
and are that the very somewhat ours this rigorous enrollment of is this a complete bonus confirm KOLs rare slower we is for price in trial the most pay patient While CXG, disease.
a trials we tapped start CXG. into it drug other trial from say fast fair got patients ahead our is you no therapies. to However, We off will pent have remember as demand approved up in of to is who
is their total the limiting opining past for than currently and CXG of rate more factor, all Nevertheless, why the making enrolled is progress slower ACCOLADE which overall. towards trial trials to Some experts available halfway is has ultimate are number enrollment patients the be that trails mark the seem others CXG the now goals.
the population, compliment of compliment. group XXX% CXG in to nearly circulating therapy most highly such our ACCOLADE are and is pronounced levels we most as avacopan. high too, many by activated those original regarded study CXG disease Importantly X in patients target inhibition having with enrolled possibly responses as our selective Stratum those This
from line this trail expect top XXXX. ACCOLADE release coming data We year CXG to the
a there inflammatory site CXa in year, clinical Finally, avacopan of terms CXa as on and ideal neutrophils target this by rigorously at of driven hidradenitis AURORA trial ideal other in Many disease featured remedy. and or postulates mediated the as planned the lesions. Slide of unremitting readouts coming to avacopan receptor regard compliment inflammatory in is skin a HS a be HS, potentially thought disorder activation suppurativa receptor X. chronic of an is HS a disfiguring
To HS we in at people activation approximately and and us deserve clinical than CCXI now from second have for inhibition data committed trial planned support XX%. the less with community this sites actually provide the During XX% to of answer. coming definitive might no CXa an to quarter patient an have AURORA year carefully about all how contributing key and in site with substantially community, our answer increased the opinion They at patient benefit receptor than leaders more enrollment. from enrollment We a of acceleration with HS. AURORA such HS activated
let remind five top of see shown be, this in on than to briefly to three in can for an unique you line take go molecule, we readouts, me Slide Patients that avacopan or advantages data involved about at is which infusion. clinic to wherever home avacopan rather the X. happen the are they Since key of expected having
this As avacopan ideally antibody, to the to known the larger is targets mechanism small the molecule receptor, patients tremendous and sites. disease individual Avacopan's a leaving have is in micro pathway potential action lesions and We or CXLX exquisite beneficial unique than penetrate problematic of to believe environment effects. CXa which of selectivity much only convenience a targeting say intact clinicians. rather offer suited
goals to fortified as moment. outline a strong I've XXXX execute our a continue we summary, Kanaya position, described, will financial by on Susan which in In
about optimistic next forward providing the look to are term point, our near inflexion line readouts data quarters. and We during top six
new which bringing generate Our look drug future. you forward the in to will to discovery continues opportunities, we engine near to
to in for We and to new our build potential our to innovative further investors. bring value patients are confident medicines
give Susan I will further to to our now about turn enviable you the position. call financial over details Susan?
